Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's financial performance shows improvement with increased revenue, reduced net loss, and better gross margin. However, the lack of specific strategic updates, regulatory hurdles, and negative cash flow from operations are concerns. The absence of shareholder return discussions and unclear management responses in the Q&A add uncertainty. Overall, the mixed signals suggest a neutral outlook.
Key Financial Performance
Revenue Revenue for the half year ended December 31, 2025, was $32.5 million, representing a 15% increase year-over-year. This growth was primarily driven by increased sales of our lead product in key markets.
Net Loss Net loss for the period was $18.7 million, an improvement from the $22.3 million net loss in the prior year. The reduction in net loss was due to cost optimization measures and increased revenue.
Gross Margin Gross margin improved to 72%, up from 68% in the previous year. This improvement was attributed to better operational efficiencies and a favorable product mix.
Operating Expenses Operating expenses were $25 million, a 5% decrease year-over-year. The decrease was due to stringent cost control measures implemented during the period.
Cash Flow Cash flow from operations was negative $5 million, compared to negative $8 million in the prior year. The improvement was due to better working capital management and increased revenue.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Risks from forward-looking statements: The company acknowledges that forward-looking statements are subject to important factors that could cause actual results to differ materially from expectations. This includes uncertainties in future events and the potential for unforeseen challenges.
Regulatory hurdles: The company’s filings with the SEC highlight the potential for regulatory challenges that could impact the approval and commercialization of its products.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Forward-looking statements: The company will be making forward-looking statements that represent the company's intentions, expectations or beliefs concerning future events. These forward-looking statements are qualified by important factors set forth in today's announcement and the company's filings with the SEC, which could cause actual results to differ materially from those in such forward-looking statements. In addition, any forward-looking statements represent the company's views only at the date of this webcast and should not be relied upon as representing the company's views of any subsequent date. The company specifically disclaims any obligations to update such statements.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASX Home
Advisory Executive
Brayer Cantor
CEO MD
Canaccord Genuity
Cantor Fitzgerald
Chairman Scientific
Co Research
Corp
Director OBrien
Division Madeleine
Division Okunewitch
Division PM
EST Hello
Hello result
Home Investor
Investor page
Itescu Founder
Joint Secretary
Madeleine Williams
OBrien Chief
Officer Edward
Okunewitch Maxim
PM EST
Research Division
Secretary Silviu
Silviu Itescu
Williams Canaccord
conference
result announcement
view date
MESO Transcript
Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
Unknown2-27
The company's financial performance shows improvement with increased revenue, reduced net loss, and better gross margin. However, the lack of specific strategic updates, regulatory hurdles, and negative cash flow from operations are concerns. The absence of shareholder return discussions and unclear management responses in the Q&A add uncertainty. Overall, the mixed signals suggest a neutral outlook.
Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript
Unknown8-29
The earnings call presents a mixed picture: strong gross margins and positive market access developments are offset by increased expenses and non-cash losses. The Q&A reveals some uncertainty, particularly regarding sales projections and treatment kit data. The company's strategic focus on trials and market expansion is promising, but lack of specific guidance tempers enthusiasm. Given these factors, the stock price is likely to remain stable in the short term.
Mesoblast Limited (NASDAQ:MESO) Q2 2025 Earnings Call Transcript
Positive3-3
The earnings call indicates strong financial metrics with a reduced net operating cash spend and positive revenue expectations from RYONCIL. Despite regulatory and competitive risks, the FDA approval and positive payer feedback are promising. The absence of a shareholder return plan is a slight drawback, but the overall sentiment is positive due to the product's market potential and the company's proactive approach to launching and expanding RYONCIL.
Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript
Unknown2-28
The company's earnings call reveals mixed signals: positive developments like increased enrollment sites for trials and positive payer feedback are offset by competitive pressures and significant financial losses. The Q&A section highlights positive payer feedback and rapid enrollment plans, but unclear timelines for FDA discussions raise concerns. The lack of a shareholder return plan and financial risks such as a substantial loss after tax further moderate the outlook. Given these factors, the stock price is likely to remain stable, leading to a neutral prediction.
MESO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
